A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel

Markus Cornberg(Medizinische Hochschule Hannover), Homie Razavi(Center for Disease Analysis), A. Albertí(University of Padua), Enos Bernasconi(Ospedale regionale di Lugano), Marı́a Buti(Vall d'Hebron Hospital Universitari), Curtis Cooper(University of Ottawa), Olav Dalgård(Oslo University Hospital), John F. Dillion(University of Dundee), Robert Flisiak(Medical University of Białystok), Xavier Forns(Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas), Soňa Fraňková(Institute of Clinical and Experimental Medicine), Adrian Goldiș(Victor Babeș University of Medicine and Pharmacy Timișoara), Ioannis Goulis(Aristotle University of Thessaloniki), Waldemar Halota(Nicolaus Copernicus University), Béla Hunyady(University of Pecs), Martin Lagging(University of Gothenburg), Angela Largen(Center for Disease Analysis), Michael Makara(Unified Szent István and Szent László Hospital), Spilios Manolakopoulos(Hippocration General Hospital), Patrick Marcellin(Université Paris Cité), Rui Tato Marinho(Hospital de Santa Maria), Stanislas Pol(Délégation Paris 5), Thierry Poynard(Sorbonne Université), Massimo Puoti(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Olga Sagalova(Chelyabinsk State Medical Academy), Scott Sibbel(Center for Disease Analysis), Krzysztof Simon(Wroclaw Medical University), Carolyn Wallace(Center for Disease Analysis), Kendra A. Young(Center for Disease Analysis), Cihan Yurdaydın(Ankara University), Eli Zuckerman(Carmel Medical Center), Francesco Negro(Centre universitaire de médecine générale et santé publique, Lausanne), Stefan Zeuzem(Goethe University Frankfurt)
Liver International
June 8, 2011
Cited by 409Open Access
Full Text

Abstract

BACKGROUND AND AIM: Decisions on public health issues are dependent on reliable epidemiological data. A comprehensive review of the literature was used to gather country-specific data on risk factors, prevalence, number of diagnosed individuals and genotype distribution of the hepatitis C virus (HCV) infection in selected European countries, Canada and Israel. METHODOLOGY: Data references were identified through indexed journals and non-indexed sources. In this work, 13,000 articles were reviewed and 860 were selected based on their relevance. RESULTS: Differences in prevalence were explained by local and regional variances in transmission routes or different public health measures. The lowest HCV prevalence (≤ 0.5%) estimates were from northern European countries and the highest (≥ 3%) were from Romania and rural areas in Greece, Italy and Russia. The main risk for HCV transmission in countries with well-established HCV screening programmes and lower HCV prevalence was injection drug use, which was associated with younger age at the time of infection and a higher infection rate among males. In other regions, contaminated glass syringes and nosocomial infections continue to play an important role in new infections. Immigration from endemic countries was another factor impacting the total number of infections and the genotype distribution. Approximately 70% of cases in Israel, 37% in Germany and 33% in Switzerland were not born in the country. In summary, HCV epidemiology shows a high variability across Europe, Canada and Israel. CONCLUSION: Despite the eradication of transmission by blood products, HCV infection continues to be one of the leading blood-borne infections in the region.


Related Papers

No related papers found

Powered by citation graph analysis